作者
Daniela Sarnataro, Simona Pisanti, Antonietta Santoro, Patrizia Gazzerro, Anna Maria Malfitano, Chiara Laezza, Maurizio Bifulco
发表日期
2006/10/1
期刊
Molecular pharmacology
卷号
70
期号
4
页码范围
1298-1306
出版商
American Society for Pharmacology and Experimental Therapeutics
简介
The endocannabinoid system has been shown to modulate key cell-signaling pathways involved in cancer cell growth. In this study, we show that cannabinoid receptor type 1 (CB1) antagonist Rimonabant (SR141716) inhibited human breast cancer cell proliferation, being more effective in highly invasive metastatic MDA-MB-231 cells than in less-invasive T47D and MCF-7 cells. The SR141716 antiproliferative effect was not accompanied by apoptosis or necrosis and was characterized by a G1/S-phase cell cycle arrest, decreased expression of cyclin D and E, and increased levels of cyclin-dependent kinase inhibitor p27KIP1. We have also shown that SR141716 exerted a significant antiproliferative action, in vivo, by reducing the volume of xenograft tumors induced by MDA-MB-231 injection in mice. On the other hand, at the concentration range in which we observed the antiproliferative effect in tumor cells, we …
引用总数
200620072008200920102011201220132014201520162017201820192020202120222023202416209996151079636310743